Novo Nordisk saw price pressure for its GLP-1 drugs Ozempic and Wegovy. Investors want to know how Eli Lilly’s Zepbound performed.
Communicating your story to the Street
Novo Nordisk saw price pressure for its GLP-1 drugs Ozempic and Wegovy. Investors want to know how Eli Lilly’s Zepbound performed.